에 대한 최신 뉴스 Align Tech (NASDAQ:ALGN) 주식

Align Tech

Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.

Politics

Trading Ideas

ALGN

NVDA

PYPL

VRTX

WYNN

전 대통령 도널드 트럼프는 이전에 백악관에서 4년 동안 재직한 경험이 있기 때문에, 그가 2024년 대선에서 승리하여 두 번째 임기를 수행할 경우 어떤 주식과 섹터가 혜택을 볼 수 있을지 투자자들이 파악하는 데 도움이 될 수 있다.

트럼프 대통령 시기인 2017년 S&amp;P 500에서 가장 우수한 성과를 거둔 10개 주식: 역사가 반복될까?

News

Movers

BEKE

FSLR

FUTU

NTES

TSLA

미국에 상장된 중국 기업들의 주가는 약세로 인해 지난주 상승폭을 잃었다. 중국은 투자자들의 경기 부양 기대에 미치지 못해 2주 연속 상승세를 보인 후 하락세를 보인 것으로 알려졌다.

리 오토, 테슬라 및 니오는 지난주 최악의 성과를 보인 11개 대형주 중 일부 (10월 7일 - 10월 11일)

Earnings

Guidance

Health Care

After-Hours Center

치과 교정에 사용되는 3D 디지털 스캐너와 인비절라인(Invisalign) 투명 교정 장치를 생산하는 미국 제조업체 얼라인 테크놀로지(NASDAQ:ALGN)의 주가는 회사가 2분기 재무 결과를 보고하고 약한 가이던스를 발표한 후 수요일 시간외 세션에서 하락했다.

얼라인 테크놀로지는 약한 2분기 매출 실적과 3분기 가이던스 발표 후 주가 하락

Align Technology Inc

Leerink Partners upgraded Align Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), citing upside opportunities throughout 2025 given gross <a href="https://www.benzinga.com/quote/ALGN" target="_blank" rel="noreferrer noopener">margin expansion opportunities</a>.
Align Technology — a medical device company that manufactures and sells dental aligners, scanners, and software for digital orthodontics and restorative dentistry — will benefit from improving consumer sentiment, easing comps and continued equipment traction with Lumina.
In October, Align Technology announced that it is planning to repurchase $275 million of its common stock through open market repurchases under its $1 billion stock repurchase program, which was approved by Align&#8217;s Board of Directors <a href="https://www.benzinga.com/pressreleases/24/10/b41543440/align-technology-announces-275-million-open-market-repurchase" target="_blank" rel="noreferrer noopener">in January 2023</a>.
Also Read:<a target="_blank" href="https://www.benzinga.com/24/12/42470172/what-does-dental-player-pattersons-41-billion-deal-mean-for-other-players-analyst-outlines" rel="noreferrer noopener"> What Does Dental Player Patterson&#8217;s $4.1 Billion Deal Mean For Other Players?</a>
Analyst Michael Cherny still does not anticipate an entirely risk-free situation. Average selling price (ASP) pressures could lead to short-term fluctuations, and unpredictable consumer data may cause stock volatility.
However, the analyst writes the positives outweigh the negatives.
Align has consistently outperformed competitors through innovation, competitive advantages, and relationships with dentists.
Cherny adds that the previous market perform rating reflected expectations of a weaker fiscal year in 2024 due to challenging economic conditions and uncertainty about the earnings impact of new product launches.
Leerink sees a clearer path for growth in fiscal 2025. Operational efficiencies will likely drive additional profit gains beyond that year.
Leerink has upgraded Align Technology from Market Perform to Outperform, with a price target of $280 from $235.
In the third quarter, Align Tech reported adjusted EPS of $2.35, better than the consensus of $2.31, while sales increased 1.8% to $977.9 million, below the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41500216/align-technology-announces-third-quarter-2024-financial-results" rel="noreferrer noopener">consensus of $987.34 million</a>.
Most recently, Align Technology received a CE Mark in Europe for Align&#8217;s Invisalign <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42098923/align-technology-has-received-ce-mark-in-europe-for-the-invisalign-palatal-expander-system-to-addr" rel="noreferrer noopener">Palatal Expander System</a>.
The Invisalign Palatal Expander System has also completed registration with MHRA for the United Kingdom and overseas territories.
Price Action: Align stock is up 6.45% at $221.68 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42820858/xpeng-partners-with-rti-for-next-gen-communication-framework-in-electric-vehicles" target="_blank" rel="noreferrer noopener">XPeng Teams Up With Real-Time Innovations For Smarter EVs: Details</a></li>
</ul>
Image: Shutterstock

Analyst Color

Analyst Ratings

General

Align Technology Boosted By Improving Sentiment, Easing Comps, Margins, Earns Analyst Upgrade

WIIM

Align Technology shares are trading higher after Leerink Partners upgraded the stock from Market Perform to Outperform and raised its price target from $235 to $280.

Leerink Partners analyst Michael Cherny upgrades Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) from Market Perform to Outperform and raises the price target from $235 to $280.

Upgrades

Price Target

Leerink Partners Upgrades Align Tech to Outperform, Raises Price Target to $280

B of A Securities analyst Michael Ryskin maintains Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Underperform and raises the price target from $200 to $206.

B of A Securities Maintains Underperform on Align Tech, Raises Price Target to $206

On Wednesday,&nbsp;Patient Square Capital, a healthcare investment firm, agreed to acquire&nbsp;Patterson Companies, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>), a dental and animal health product distributor, for&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42433177/patterson-companies-announces-definitive-agreement-to-be-acquired-by-patient-square-capital-for-31" rel="noreferrer noopener">approximately $4.1 billion</a>.
During its second-quarter earnings release, the company announced it is exploring strategic options, including a sale or merger,&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42342667/dental-supplies-patterson-companies-evaluates-strategic-alternatives-after-mixed-q2-earnings-amid-challenging-end-market-environment" rel="noreferrer noopener">to boost shareholder value</a>.
William Blair notes that based on Patient Square Capital&#8217;s portfolio, which doesn&#8217;t include dental or animal health companies, regulatory hurdles for this deal are unlikely.
Additionally, the analyst&#8217;s dental valuation analysis suggests the offer for Patterson is strong, making it unlikely that higher bids will emerge during the 40-day window for competing offers.
The valuation analysis includes Align Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), Dentsply Sirona Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>), Henry Schein Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>), Envista Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVST#NYSE">NVST</a>) and Europe-listed Straumann Holding.
William Blair writes that most dental companies they cover are trading at or near their lowest valuations in 15 years, as investor interest has declined due to ongoing macroeconomic challenges.
Most recently,&nbsp;Dentsply Sirona revised its 2024 outlook due to market pressures impacting U.S. equipment, legislative changes affecting the direct-to-consumer aligner business model, and the voluntary&nbsp;suspension of sales, marketing, and shipments of Byte Aligners <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41814727/dentsply-sirona-stock-sinks-on-dismal-2024-guidance-blames-macroeconomic-competitiv" rel="noreferrer noopener">and Impression Kits</a>.
Henry Schein&#8217;s third-quarter global dental segment sales were $1.9 billion, down 1.6%, and medical segment sales increased by 2.9% (down 4.8% internally) <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41752173/henry-schein-q3-earnings-sees-recovery-from-cyber-incident-says-dental-equipment-business-shows-sta" rel="noreferrer noopener">to $1.1 billion</a>.
While it&#8217;s still early to gauge investor reactions, the analyst is considering whether Patterson&#8217;s acquisition might stabilize valuations and boost demand in the dental sector.
The analyst writes the move could support valuations and signal a potential recovery in the market, making many dental stocks appealing from a risk/reward perspective.
Among these, William Blair sees Align as having the greatest potential for stock growth, driven by improving market conditions and gains in both earnings and valuation.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42465586/gevo-and-lg-chem-push-ahead-on-eto-commercialization-for-sustainable-aviation-and-bio-propylene-markets" target="_blank" rel="noreferrer noopener">Gevo And LG Chem Double Down On Ethanol-To-Olefins Tech: Details</a></li>
</ul>
Photo via Shutterstock

Large Cap

HSIC

NVST

PDCO

XRAY

What Does Dental Player Patterson's $4.1 Billion Deal Mean For Other Players?

<ul>
<li>Invisalign&#xAE; Palatal Expanders offer doctors a removeable, safe, and clinically effective alternative to traditional palatal expanders.</li>
<li>With Invisalign First&#x2122; aligners and Invisalign&#xAE; Palatal Expanders, Align Technology now provides doctors with a full early intervention treatment solution, including both skeletal (orthopedic) and dental (orthodontic) arch expansion.</li>
<li>The Invisalign Palatal Expander System has also completed registration with the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA).</li>
<li>Both approvals are for broad patient applicability, including growing children, teens, and adults (with surgery or other techniques).</li>
</ul>
Align Technology, Inc. ("Align") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) a leading global medical device company that designs, manufactures, and sells the Invisalign&#xAE; System of clear aligners, iTero&#x2122; intraoral scanners, and exocad&#x2122; CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it has received CE Mark in Europe under the Medical Device Regulation (MDR 2017/745) for Align's Invisalign&#xAE; Palatal Expander System. The Invisalign Palatal Expander System has also completed registration with MHRA for the United Kingdom and overseas territories.
Both approvals are for broad patient applicability, including growing children, teens, and adults (with surgery or other techniques).
These approvals mark a significant milestone in Align's efforts to enhance clinical outcomes and efficiency in orthodontics.
The Invisalign Palatal Expander System is a modern and innovative direct 3D printed device based on proprietary and patented technology. Invisalign Palatal Expanders are intended for use in rapid expansion and subsequent holding of skeletal and/or dental narrow maxilla (upper jaw) with primary, mixed, or permanent dentition during treatment of patients.

Global

Align Technology Has Received CE Mark In Europe For The Invisalign Palatal Expander System

Needham analyst David Saxon reiterates Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Hold.

Reiteration

Needham Reiterates Hold on Align Tech

Former President Donald Trump previously spent four years in the White House, which could help investors know which stocks and sectors could benefit under a second term if he wins the<a href="https://www.benzinga.com/topic/2024-election"> 2024 presidential election.</a>
Here's a look back at the top performing stocks in 2017, Trump's first year in the White House.
Top Performing 2017 Stocks: The stock markets saw impressive gains in 2017, which were among the best ever for a president's <a href="https://www.benzinga.com/markets/futures/18/01/11066769/the-stock-markets-rally-under-trump-among-the-best-ever-heres-how-his">first year in the White House.</a>
The S&amp;P 500, which is tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), gained 21.7% in 2017, an impressive gain to the +12.0% increase in 2016, as presidential election years have historically produced outperformance to other years.
With the potential for Trump to be re-elected in 2024, here's a look back at the top 10 performing stocks in the S&amp;P 500 from 2017, as reported previously by <a href="https://www.marketwatch.com/story/biggest-sp-500-winners-and-losers-of-2017-tech-health-care-and-home-builders-lead-2017-12-29">Marketwatch</a>.
<ol>
<li>NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>): +132%, utilities</li>
<li>Align Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>): +131%, health care</li>
<li>Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>): +103%, health care</li>
<li>Wynn Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>): +95%, consumer discretionary</li>
<li>Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>): +89%, industrials</li>
<li>Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>): +88%, technology</li>
<li>D.R. Horton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>): +87%, consumer discretionary, homebuilders</li>
<li>PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>): +87%, technology</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>): +81%, technology</li>
<li>Pulte Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>): 81%, consumer discretionary, homebuilders</li>
</ol>
The top 10 stocks in 2017 likely saw gains related to reasons that didn't have to do with Trump being president, but there are also some common themes and some potential connections to the former president.
The results show that health care, consumer discretionary and technology stocks were among the top-performing sectors.
Of particular note is Micron and Nvidia, both ranking in the top 10, a potential positive for the semiconductor sector under a Trump presidency.
Another key trend could be two homebuilders ranking among the top 10 best-performing stocks in 2017. Homebuilders have been a popular sector to watch under a possible Kamala Harris win with the current vice president and Trump running on a platform of <a href="https://www.benzinga.com/general/politics/24/08/40424431/harris-warns-trump-tax-plan-will-devastate-americans-vows-to-go-after-bad-actors-behind-food-pri">building more homes</a> for the middle class.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent102824">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: While past results don't guarantee future results, sometimes market trends can show patterns and signs of what to come.
Based on the top-performing stocks in 2017, investors may want to prepare for some <a href="https://www.benzinga.com/markets/equities/24/10/41213583/what-a-trump-win-could-mean-for-financial-energy-stocks-lessons-from-2016">exposure to health care</a>, utilities, semiconductors and homebuilders if Trump wins the 2024 election.
With less than two weeks until the 2024 election, investors are likely positioning their portfolios based on a Trump or Harris win in some regards. With a close election predicted, investors may want to look to sectors that could benefit under either candidate.
Freedom Capital Markets Chief Global Strategist Jay Woods previously shared some <a href="https://www.benzinga.com/etfs/sector-etfs/24/08/40515453/exclusive-trump-or-harris-12-stocks-2-etfs-could-win-no-matter-whos-president-says-market-strate">sectors and stocks to watch</a> with Benzinga that could benefit regardless of whether Trump or Harris wins the 2024 election.
Woods named defense stocks and cybersecurity stocks as two of the top sectors to watch ahead of the 2024 election.
"I think you've got to watch this sector closely," Woods said of the defense sector.
Woods said defense stocks could continue to benefit from geopolitical concerns and a lot of bad things happening in the world.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/sports-betting/24/10/41534317/if-trump-wins-2024-election-in-landslide-bettors-could-make-5x-20x-their-bets-at-uk-sports">If Trump Wins 2024 Election In Landslide, Bettors Could Make 5X, 20X Their Bets At UK Sportsbook</a></li>
</ul>
Photo: Shutterstock

These 10 Stocks Were The Best S&P 500 Performers In 2017 When Trump Was President: Will History Repeat Itself?

Align Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) shares are trading higher by 3% to $223.00 Friday morning after the company announced plans to repurchase $275 million of its common stock as part of a $1 billion stock repurchase program <a href="https://www.benzinga.com/pressreleases/24/10/b41543440/align-technology-announces-275-million-open-market-repurchase">approved in January 2023</a>.
What Else: CFO John Morici highlighted that this buyback reflects confidence in the company&#8217;s financial strength and growth potential within the orthodontic industry. 
The repurchase will occur through open market transactions under a Rule 10b5-1 trading plan, concluding by January 2025, and will be funded from Align's cash reserves. As of September 30, Align reported 74.8 million shares outstanding and over $1 billion in cash.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41536518/bitcoin-gains-ethereum-dogecoin-muted-amid-tesla-powered-stocks-rally-analyst-highlights-m">Bitcoin Gains, Ethereum, Dogecoin Muted Amid Tesla-Powered Stocks Rally</a>
Why This Matters: A stock repurchase often leads to a rise in the stock price because it reduces the number of shares outstanding, effectively increasing the value of each remaining share. 
This buyback signals that Align Technology's management is confident in the company&#8217;s financial health and growth prospects, making the stock more attractive to investors. 
Additionally, by using cash reserves to buy back shares, Align demonstrates strong cash flow, which can reinforce investor confidence. These factors together often drive up demand for the stock.
Read Also: <a href="https://www.benzinga.com/markets/equities/24/10/41536387/cathie-woods-ark-sells-22m-worth-of-tesla-shares-following-blockbuster-q3-rally">Cathie Wood&#8217;s Ark Sells $22M Worth Of Tesla Shares Following Blockbuster Q3 Rally</a>
<h2 class="wp-block-heading">Is ALGN A Good Stock To Buy?</h2>
An investor or trader's decision to buy or sell a stock is unique to their time horizon and risk tolerance. Many typical investors evaluate earnings growth and valuation on a particular stock before making a decision. 
For example, for Align Tech, you'll notice that earnings in its last quarter grew 1.73% <a href="https://www.benzinga.com/quote/ALGN/earnings">source</a>. As an investor, you'll want to decide whether that's better or worse than what you'd like to see among stocks in your portfolio. 
There are many different valuation metrics that may help you make a decision. Find more on <a href="https://www.benzinga.com/quote/ALGN">Align Tech's quote page</a>, or if you'd like a deeper dive in an advanced program, try <a href="https://pro.benzinga.com">Benzinga PRO</a> for free.
ALGN has a 52-week high of $335.40 and a 52-week low of $176.34.

Why Align Technology (ALGN) Stock Is Trading Higher

Align Technology shares are trading higher after the company announced it plans to purchase $275 million worth of stock in the open market as part of its $1 billion repurchase program.

Align Technology, Inc. ("Align") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), a leading global medical device company that designs, manufactures, and sells the Invisalign&#xAE; System of clear aligners, iTero&#x2122; intraoral scanners, and exocad&#x2122; CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it is planning to repurchase $275 million of Align's common stock through open market repurchases under Align's $1.0 billion stock repurchase program that was approved by Align's Board of Directors in January 2023.

Buybacks

Align Technology Plans $275M Open Market Repurchase Under Align's $1B Stock Repurchase Program

Morgan Stanley analyst Erin Wright maintains Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Overweight and lowers the price target from $310 to $280.

Morgan Stanley Maintains Overweight on Align Tech, Lowers Price Target to $280

Stifel analyst Jonathan Block maintains Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Buy and lowers the price target from $285 to $275.

Stifel Maintains Buy on Align Tech, Lowers Price Target to $275

Evercore ISI Group analyst Elizabeth Anderson maintains Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Outperform and lowers the price target from $270 to $250.

Evercore ISI Group Maintains Outperform on Align Tech, Lowers Price Target to $250

Align Technology shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.

Whales with a lot of money to spend have taken a noticeably bullish stance on Align Tech.
Looking at options history for Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 37% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $249,770 and 4, calls, for a total amount of $284,927.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $125.0 and $212.5 for Align Tech, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Align Tech's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Align Tech's significant trades, within a strike price range of $125.0 to $212.5, over the past month.
<h3>Align Tech Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729781127_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$124.9</td>
<td>$122.5</td>
<td>$122.5</td>
<td>$125.00</td>
<td>$183.7K</td>
<td style="text-align: right;">15</td>
<td>15</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.2</td>
<td>$1.6</td>
<td>$2.0</td>
<td>$170.00</td>
<td>$120.0K</td>
<td style="text-align: right;">171</td>
<td>1.2K</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.7</td>
<td>$2.15</td>
<td>$2.3</td>
<td>$170.00</td>
<td>$45.7K</td>
<td style="text-align: right;">171</td>
<td>201</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/01/24</td>
<td>$2.4</td>
<td>$2.1</td>
<td>$2.1</td>
<td>$212.50</td>
<td>$42.0K</td>
<td style="text-align: right;">6</td>
<td>201</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.5</td>
<td>$0.95</td>
<td>$2.1</td>
<td>$170.00</td>
<td>$42.0K</td>
<td style="text-align: right;">171</td>
<td>600</td>
</tr>
</tbody>
</table>

<h3>About Align Tech</h3>
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
Having examined the options trading patterns of Align Tech, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Align Tech</h3>
<ul>
<li>With a volume of 793,567, the price of ALGN is up 5.94% at $220.0. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 97 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Align Tech with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Unpacking the Latest Options Trading Trends in Align Tech

Piper Sandler analyst Jason Bednar maintains Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Overweight and lowers the price target from $285 to $275.

Piper Sandler Maintains Overweight on Align Tech, Lowers Price Target to $275

Baird analyst Jeff Johnson maintains Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Outperform and lowers the price target from $325 to $276.

Baird Maintains Outperform on Align Tech, Lowers Price Target to $276

Align Technology shares are trading lower after the company reported mixed Q3 financial results.

Mizuho initiated coverage of Align Technology (ALGN) with an Outperform rating and $295 price target Nearly every subsegment of the global dental/o...

Align Technology initiated with an Outperform at Mizuho

LRT Capital Management November 2024 Investor Update

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

GE Vernova initiated, Merck upgraded: Wall Street's top analyst calls

Steven Valiquette, an analyst from Mizuho Securities, has initiated a new Buy rating on Align Tech (ALGN). Steven Valiquette has given his Buy rati...

Strategic Buy Recommendation for Align Technology Amidst Market Recovery and Growth Potential

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Revance Therapeutics (RVNC – Research Report), Syn...

Analysts Conflicted on These Healthcare Names: Revance Therapeutics (RVNC), Syndax Pharmaceuticals (SNDX) and Align Tech (ALGN)

BNY Mellon Small/Mid Cap Growth Fund Q3 2024 Commentary

BofA raised the firm's price target on Align Technology (ALGN) to $206 from $200 and keeps an Underperform rating on the shares. The Life Sciences ...

Align Technology price target raised to $206 from $200 at BofA

Align Technology: Economic Headwinds Cloud An Attractive Growth Story

Align upgraded by Leerink to outperform from market perform

Stifel Nicolaus analyst Jonathan Block maintained a Buy rating on Align Tech (ALGN – Research Report) yesterday and set a price target of $275.00. ...

Positive Outlook for Align Technology: Strategic Restructuring and Earnings Growth Drive Buy Recommendation

ALEC

APOS

AXON

AZPN

BKAG

BKCI

BKEM

BKGI

BKHY

BKIE

BKLC

BKMC

BKSE

BKUI

CASY

CELH

CFLT

CGNX

CIGI

COHR

CSGP

DINO

DOCS

DXCM

ENSG

EXPO

FRPT

GDRX

HUBS

INSP

KVYO

LFMD

MKTX

PLNT

PSTG

RGEN

RVNC

SNDX

SOLV

SRPT

TALK

TNET

TRMB

VEEV

Press Releases

Align Technology Introduces Invisalign Smile Architect™ With Multiple Treatment Plans, Further Enabling Ortho Restorative Digital Dentistry Treatment Options

Align Technology Announces iTero™ Intraoral Scanner Product Innovations That Enhance Digital Dentistry Workflows and Integrated Treatment Options in Oral Health, Restorative, and Ortho Treatment in General Dentistry Practices

ALIGN TECHNOLOGY ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTS

Frank Quinn to Rejoin Align Technology as Executive Vice President and Managing Director of the Americas Region

Align Technology Announces $275 Million Open Market Repurchase

Align Technology to Speak at Upcoming Financial Conferences

Align Technology Opens 2025 Annual Research Program to Advance Orthodontic and Dental Patient Care

Align Technology Hosts the 2024 Invisalign™ Ortho Summit, Its Premier Education Event to Enhance Digital Practice Transformation and Treatment Experiences for Patients, Teams, and Practices

Align Technology Has Received CE Mark in Europe for the Invisalign® Palatal Expander System to Address Skeletal and Dental Expansion in Growing Patients, Including Teenage Patients

Align Technology to Announce Fourth Quarter and 2024 Results on February 5, 2025

Avanos Medical

Bioventus

Cerus

The Cooper Companies, Inc. - Common Stock

Cooper Companies

Embecta

Establishment Labs Holdings Inc. - Common Shares

Establishment Labs Hldgs

Haemonetics

ICU Medical

OrthoPediatrics

Lantheus Holdings

Merit Medical Systems, Inc. - Common Stock

Merit Medical Systems

Neogen

InspireMD

OraSure Technologies, Inc. - Common Stock

OraSure Technologies

Rockwell Medical

RxSight

Sanara MedTech

Solventum

Staar Surgical

TELA Bio

UFP Techs

Utah Medical Products, Inc. - Common Stock

Utah Medical Products

WORK Medical Technology Group LTD - Ordinary Shares

WORK Medical Technology

Dentsply Sirona

Xtant Medical Holdings, Inc. Common Stock

Xtant Medical Hldgs

Leerink Partners

B of A Securities

Morgan Stanley

Stifel

Evercore ISI Group

전 대통령 도널드 트럼프는 이전에 백악관에서 4년 동안 재직한 경험이 있기 때문에, 그가 <a href="https://www.benzinga.com/topic/2024-election">2024년 대선</a>에서 승리하여 두 번째 임기를 수행할 경우 어떤 주식과 섹터가 혜택을 볼 수 있을지 투자자들이 파악하는 데 도움이 될 수 있다.
트럼프가 백악관에 처음 입성한 2017년에 가장 잘 수행된 주식들을 살펴보겠다.
2017년 최고의 주식들: 주식 시장은 2017년에 인상적인 상승세를 보였으며, 이는 대통령의 <a href="https://www.benzinga.com/markets/futures/18/01/11066769/the-stock-markets-rally-under-trump-among-the-best-ever-heres-how-his">첫 해에 가장 좋은 성과 중 하나</a>였다.
SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)가 추적하는 S&amp;P 500은 2017년에 21.7% 상승했는데, 이는 2016년 +12.0% 상승에 비해 인상적인 상승률이다. 역사적으로 대통령 선거 연도가 다른 연도에 비해 뛰어난 성과를 거두었기 때문이다.
트럼프가 2024년에 재선될 가능성이 있는 만큼, 2017년 S&amp;P 500에서 가장 성과가 좋았던 10개 주식을 살펴보겠다. 이는 이전에 <a href="https://www.marketwatch.com/story/biggest-sp-500-winners-and-losers-of-2017-tech-health-care-and-home-builders-lead-2017-12-29">마켓워치</a>에 의해 보도된 내용다.
<ol>
<li>NRG 에너지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>): +132%, 유틸리티</li>
<li>얼라인 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>): +131%, 헬스케어</li>
<li>버텍스 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>): +103%, 헬스케어</li>
<li>윈 리조트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>): +95%, 소비재</li>
<li>보잉 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>): +89%, 산업재</li>
<li>마이크론 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>): +88%, 기술</li>
<li>D.R. 호튼 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>): +87%, 소비재, 주택 건설업체</li>
<li>페이팔 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>): +87%, 기술</li>
<li>엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>): +81%, 기술</li>
<li>풀테 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>): 81%, 소비재, 주택 건설업체</li>
</ol>
2017년의 상위 10개 주식들은 트럼프가 대통령인 것과 관련이 없는 이유로 상승세를 보였을 가능성이 있지만, 몇 가지 공통된 주제가 있으며 전 대통령과의 잠재적인 연결고리도 있다.
결과적으로 헬스케어, 소비재 및 기술 주식들이 상위 성과를 보이는 섹터로 나타났다.
특히 마이크론과 엔비디아가 모두 상위 10위 안에 든 점은 주목할 만한 사항으로, 이는 트럼프 대통령 하에서 반도체 섹터에 긍정적인 영향을 미칠 수 있다.
또한 두 개의 주택 건설사가 2017년 가장 성과가 좋았던 주식 중 두 개로 선정된 것은 중요한 추세일 수 있다. 주택 건설업체는 현재 부통령인 카멀라 해리스가 승리할 경우 주목할만한 섹터로 여겨져 왔으며, 트럼프는 중산층을 위한 <a href="https://www.benzinga.com/general/politics/24/08/40424431/harris-warns-trump-tax-plan-will-devastate-americans-vows-to-go-after-bad-actors-behind-food-pri">주택 건설 확대</a> 공약을 내세우고 있다.
알고 계셨나요?
<ul>
<li>의회가 막대한 투자를 하고 있습니다. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent102824">2024년 선거를 앞두고 그들이 매입하고 매각한 것에 대한 팁을 쉽게 알아보세요.</a></li>
</ul>
중요한 이유 (Why It&#8217;s Important): 과거의 결과가 미래의 결과를 보장하지는 않지만, 때때로 시장 추세는 패턴과 신호를 보여줄 수 있다.
2017년의 상위 성과 주식을 기반으로 볼 때, 트럼프가 2024년 대선에서 승리할 경우 투자자들은 헬스케어, 유틸리티, 반도체 및 주택 건설업체에 대한 <a href="https://www.benzinga.com/markets/equities/24/10/41213583/what-a-trump-win-could-mean-for-financial-energy-stocks-lessons-from-2016">노출을 준비</a>할 수 있다.
2024년 대선까지 2주도 채 남지 않았기 때문에, 투자자들은 트럼프나 해리스의 승리를 기준으로 포트폴리오를 조정하고 있을 가능성이 높다. 예측되는 근소한 선거 결과를 감안할 때, 투자자들은 두 후보 중 어느 쪽이 당선되더라도 혜택을 받을 수 있는 섹터를 살펴보는 것이 좋다.
프리덤 캐피털 마켓(Freedom Capital Markets)의 수석 글로벌 전략가 제이 우즈(Jay Woods)는 <a href="https://www.benzinga.com/etfs/sector-etfs/24/08/40515453/exclusive-trump-or-harris-12-stocks-2-etfs-could-win-no-matter-whos-president-says-market-strate">2024년 대선에서 트럼프나 해리스 승리 여부와 관계없이 주목해야 할 섹터와 주식</a>을 벤징가와 공유한 바 있다.
우즈는 방산 주식과 사이버 보안 주식을 2024년 대선 전 주목해야 할 두 개의 주요 섹터로 명명했다.
&#8220;이 섹터를 면밀히 주시해야 한다고 생각한다&#8221;라고 방산 섹터에 대해 우즈가 말했다.
우즈는 방산 주식이 지정학적 우려와 세계에서 발생하는 여러 문제들로 인해 계속해서 혜택을 받을 수 있다고 언급했다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/general/sports-betting/24/10/41534317/if-trump-wins-2024-election-in-landslide-bettors-could-make-5x-20x-their-bets-at-uk-sports">트럼프가 2024년 대선에서 압승할 경우, 베팅자들은 영국 스포츠북에서 베팅금의 5배, 20배를 받을 수 있다.</a></li>
</ul>
사진: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

트럼프 대통령 시기인 2017년 S&P 500에서 가장 우수한 성과를 거둔 10개 주식: 역사가 반복될까?

미국에 상장된 중국 기업들의 주가는 약세로 인해 지난주 상승폭을 잃었다. 중국은 투자자들의 경기 부양 기대에 미치지 못해 <a href="https://www.benzinga.com//node/41198527" target="_blank" rel="noreferrer noopener">2주 연속 상승세를 보인</a> 후 하락세를 보인 것으로 알려졌다.
지난주 가장 저조한 실적을 기록한 대형주 11개이다. 이들 주식이 귀하의 포트폴리오에 포함되어 있나요?
1. 넷이즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>)의 주식은 13.66% 급락하여 상승세를 잃었다.
2. 후투 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>)의 주식은 중국의 부양책 조치에 대한 투자자들의 실망으로 13.25% 하락했다.
3. KE 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>)의 주식이 13.14% 하락했다.
4. 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)의 주식은 사이버택시(Cybercab) 공개 이후 투자자들이 2026년 또는 2027년의 <a href="https://www.benzinga.com//node/41295072" target="_blank" rel="noreferrer noopener">가능성을 평가</a>하면서 12.91% 하락했다.
5. 토론토 도미니온 은행(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TD#NYSE">TD</a>)의 주식은 자금 세탁 방지 합의의 일환으로 회사가 약 30억 달러의 벌금을 지불하고 성장 제한에 직면할 것으로 예상된다는 <a href="https://www.benzinga.com//node/41271816" target="_blank" rel="noreferrer noopener">보도가 나온 후</a> 지난주 10.52% 하락했다.
6. 비스트라(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>)의 주식은 투자자들이 중국의 부양책 조치에 실망하면서 9.48% 하락했다.
7. 퍼스트 솔라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>)의 주식은 제프리스(Jefferies)가 목표 주가를 <a href="https://www.benzinga.com/quote/FSLR/analyst-ratings" target="_blank" rel="noreferrer noopener">271달러에서 266달러</a>로 하향 조정한 후 8.50% 하락했다.
8. AES 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>)의 주식은 8.41% 하락했다.
9. 얼라인 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>)의 주식은 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/algn/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망</a>을 하향 조정한 후 8.00% 하락했다.
10. 니오(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>)의 주식은 상승세를 잃고 7.83% 하락했다.
11. 리 오토(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>)의 주식은 상승세를 잃고 7.63% 하락했다.
또한 읽어보세요:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%9A%B0%EB%B2%84-%EB%B0%8F-%EB%A1%9C%EB%B9%88%ED%9B%84%EB%93%9C%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC%EC%A4%80-11%EA%B0%9C-%EB%8C%80/" target="_blank" rel="noopener">우버 및 로빈후드는 지난주 최고 성과를 보여준 11개 대형주 중 일부 (10월 7일-10월 11일)</a></li>
</ul>
사진 출처: Tesla
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

치과 교정에 사용되는 3D 디지털 스캐너와 인비절라인(Invisalign) 투명 교정 장치를 생산하는 미국 제조업체 얼라인 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>)의 주가는 회사가 2분기 재무 결과를 보고하고 <a href="https://www.benzinga.com/pressreleases/24/07/b39942047/align-technology-announces-second-quarter-2024-financial-results" target="_blank" rel="noopener" data-google-interstitial="false">약한 가이던스를</a> 발표한 후 수요일 시간외 세션에서 하락했다.
<ul>
<li>2분기 매출: 10.3억 달러로 예상치는 10.4억 달러</li>
</ul>
<ul>
<li>2분기 EPS: 2.41달러로 예상치는 2.30달러</li>
</ul>
총 매출은 약 1,160만 달러 또는 1.1%의 외환으로 인해 불리한 영향을 받은 후 전년 대비 2.6% 증가했다.
얼라인은 이번 분기 인비절라인 투명 교정 장치 매출이 전년 동기 대비 0.1% 감소한 8억 3,170만 달러를 기록했다고 밝혔다. 이미징 시스템 및 CAD/CAM 서비스 매출은 총 1억 9,680만 달러로 전년 대비 16.1% 증가했다.
&#8220;2분기에 십대 또는 더 어린 환자 케이스를 제출한 의사 수가 전년 대비 8% 증가했으며, 이는 &#8216;성장 환자&#8217;로 알려진 어린 아이들을 치료하는 의사들의 지속적인 강세에 힘입은 것이다. 2분기 실적은 또한 기록적인 수의 의사가 케이스를 제출했고, 분기 동안 기록적인 수의 의사에게 배송되었다&#8221;고 얼라인의 사장 겸 CEO인 조 호건(Joe Hogan)이 말했다.
6월 30일 현재 회사는 현금, 현금 등가물, 유가증권으로 7억 8,210만 달러를 보유하고 있으며 회전 신용 한도에 따라 사용 가능한 3억 달러를 보유하고 있다.
가이던스: <a href="http://pro.benzinga.com/" target="_blank" rel="noopener">Benzinga Pro</a>에 따르면 얼라인의 3분기 매출은 추정치 10억 3천만 달러 대비 9억 8천만 달러에서 10억 달러에 이를 것으로 예상된다. 얼라인은 2024년 전체 매출 성장을 4~6%로 예상하고 있다.
이 회사는 계절적 추세로 인해 3분기에 투명 교정 장치 볼륨이 감소할 것으로 예상한다고 밝혔다. 얼라인은 또한 3분기 계절성으로 인해 시스템 및 서비스 매출이 순차적으로 감소할 것으로 예상한다.
ALGN의 주가 움직임: 수요일 얼라인 주식은 4.00% 하락한 235.00달러에 거래되었다.
사진: Align 제공
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>게임스탑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>)의 주가는 <a href="https://www.benzinga.com//node/39408371" target="_blank" rel="noopener" data-google-interstitial="false">연간 주주총회</a> 이후 지난주에 18.61% 하락했으며, CEO 라이언 코헨은 <a class="ticker" href="https://www.benzinga.com/news/24/06/39364816/why-are-gamestop-shares-moving-monday">비용 절감</a>을 통해 수익성을 향한 전략적 전환을 강조했다.</li>
<li>엔페이즈 에너지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>)의 주가는 JP모건이 주식에 대해 비중확대(Overweight) 의견을 유지했지만 <a href="https://www.benzinga.com//node/39413327" target="_blank" rel="noreferrer noopener">목표</a> 주가를 128달러에서 124달러로 낮추면서 17.60% 하락했다.</li>
<li>앨버말 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)의 <a href="https://www.benzinga.com//node/39336520" target="_blank" rel="noreferrer noopener">주식 가격은 11.53% 하락했다.</a></li>
<li>바이오엔텍 SE(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>)의 주가는 미 식품의약국(FDA)이 파트너인 메디링크 테라퓨틱스(Medilink Therapeutics)의 BNT326/YL202에 대한 임상 1상 시험에 대한 임상 <a href="https://www.benzinga.com//node/39362935">보류</a>를 결정한 후 지난주에 10.49% 하락했다.</li>
<li>얼라인 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>)의 주가는 파이퍼 샌들러(Piper Sandler)의 분석가가 <a class="ticker" href="https://www.benzinga.com/quote/ALGN/analyst-ratings">목표 주가를</a> 낮추면서 9.55% 하락했다.</li>
<li>퍼스트 솔라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLSR#NASDAQ">FLSR</a>)의 주식은 지난주 재니 몽고메리 스콧(Janney Montgomery Scott)이 주식의 평가를 매수에서 중립으로 <a href="https://www.benzinga.com/quote/FSLR/analyst-ratings">낮춘</a> 이후 8.87% 하락했다.</li>
<li>볼 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>)의 주식 가격은 7.29% 하락했다. 웰스파고(Wells Fargo)의 애널리스트가 주식의 <a href="https://www.benzinga.com/quote/ball/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가</a>를 낮췄다.</li>
<li>모빌아이 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>)의 주식은 7.02% 하락했다.</li>
<li>탑빌더(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>)의 주식은 6.97% 하락했다. 5월 주택 착공 및 건축 허가가 <a href="https://www.benzinga.com/real-estate/24/06/39412389/may-housing-market-blooms-inventory-and-listings-skyrocket" target="_blank" rel="noreferrer noopener">예상치를 하회하면서</a> 주택 건설업체, 건설 회사 및 주택 관련 주식의 가격이 하락했다.</li>
<li>자빌(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>)의 주식은 주가는 회사가 3분기 실적을 보고하고 <a href="https://www.benzinga.com//node/39432303" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">여러 분석가들이 전망을 하향 조정</a>한 후 5.56% 하락했다.</li>
</ol>
참고 자료: <a href="https://kr.benzinga.com/news/%eb%93%9c%eb%9e%98%ed%94%84%ed%8a%b8%ed%82%b9%ec%8a%a4%ec%99%80-%eb%8d%b8%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-10%ea%b0%9c/" target="_blank" rel="noopener">드래프트킹스와 델은 지난주 최고의 성과를 보인 10개의 대형주 중 일부 (6월 16일-6월 22일)</a>

BALL

BNTX

ENPH

MBLY

RIVN

FLSR

게임스탑과 자빌은 지난주 최악의 성과를 보인 10개의 대형주 중 일부 (6월 16일-6월 22일)

Comments

Align Tech

뉴스

에 대한 최신 뉴스 Align Tech (NASDAQ:ALGN) 주식

월요일, 10월 28, 2024

월요일, 10월 14, 2024

목요일, 7월 25, 2024

일요일, 6월 23, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌